- Home
- LPRO vs SGMT Comparison
LPRO vs SGMT Comparison
Compare LPRO & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPRO
- SGMT
- Stock Information
- Founded
- LPRO 2000
- SGMT 2006
- Country
- LPRO United States
- SGMT United States
- Employees
- LPRO N/A
- SGMT N/A
- Industry
- LPRO Finance: Consumer Services
- SGMT
- Sector
- LPRO Finance
- SGMT
- Exchange
- LPRO Nasdaq
- SGMT Nasdaq
- Market Cap
- LPRO 252.9M
- SGMT 230.3M
- IPO Year
- LPRO N/A
- SGMT 2023
- Fundamental
- Price
- LPRO $2.26
- SGMT $7.11
- Analyst Decision
- LPRO Buy
- SGMT Strong Buy
- Analyst Count
- LPRO 6
- SGMT 7
- Target Price
- LPRO $3.00
- SGMT $26.57
- AVG Volume (30 Days)
- LPRO 636.8K
- SGMT 601.4K
- Earning Date
- LPRO 11-06-2025
- SGMT 08-13-2025
- Dividend Yield
- LPRO N/A
- SGMT N/A
- EPS Growth
- LPRO N/A
- SGMT N/A
- EPS
- LPRO N/A
- SGMT N/A
- Revenue
- LPRO $16,254,999.00
- SGMT N/A
- Revenue This Year
- LPRO $311.24
- SGMT N/A
- Revenue Next Year
- LPRO $13.17
- SGMT N/A
- P/E Ratio
- LPRO N/A
- SGMT N/A
- Revenue Growth
- LPRO N/A
- SGMT N/A
- 52 Week Low
- LPRO $0.70
- SGMT $1.73
- 52 Week High
- LPRO $6.92
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- LPRO 55.53
- SGMT 39.46
- Support Level
- LPRO $2.01
- SGMT $7.01
- Resistance Level
- LPRO $2.34
- SGMT $7.68
- Average True Range (ATR)
- LPRO 0.13
- SGMT 0.51
- MACD
- LPRO 0.03
- SGMT -0.02
- Stochastic Oscillator
- LPRO 78.67
- SGMT 39.03
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.